A phase I study of B43-genistein immunoconjugate [monoclonal antibody B43-genistein-conjugate] in recurrent B-lineage acute lymphoblastic leukemia and non-Hodgkin's lymphoma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Monoclonal antibody B43 genistein conjugate (Primary)
- Indications Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Most Recent Events
- 29 Sep 2005 New trial record.